Introduction
The continuing discovery and development of novel, safe and effective medicines is expected by contemporary society. Nevertheless, the intellectual, technical and financial challenges associated with it are enormous. Despite the approval of 41 new therapeutics during 2014 (a significant 17-year high) [1] , the ability of the pharmaceutical industry to rise to these formidable challenges is periodically questioned and tentative solutions are constantly suggested [2] [3] [4] [5] [6] [7] . As a result, the field of drug research has seen significant changes over the past decades and a stronger emphasis on precompetitive, opensource models is evident [8] . One such approach, the European Lead Factory (ELF) a project of the Innovative Medicine Initiative, has recently created a collaborative lead generation platform to boost the early phases of drug discovery [9] . The state-of-the-art high-throughput screening (HTS) infrastructure and the industrial-quality Joint European Compound Collection of the ELF are made available at no cost to European research investigators, with a milestone payment system applied to any exploitation projects targeting commercialization (https://www.europeanleadfactory.eu/#). As part of the ELF open-source model, seven pharmaceutical companies (Bayer, AstraZeneca, UCB, Lundbeck, Sanofi, Merck, J&J) have contributed a total of 321,000 compounds from their proprietary collections [10] . This initial set is now being complemented with up to an additional 200,000 compounds [here termed the Public Compound Collection (PCC)] in a collaborative effort involving a unique blend of chemistry expertise from ten academic groups and six small and medium enterprises (SMEs) ( [11] and compounds curated in the ChEMBL database [12] . The Maybridge collection was chosen as a representative screening library from commercial sources because of its diversity-based character and previous use in screening collections comparisons [13] . The MLP library was selected because of the similar collaborative nature of the MLP and ELF programs, and the ChEMBL database because of the medicinal chemistry relevance of the compounds curated therein.
ELF library workflow
Library proposals submitted to the ELF Chemistry Consortium using a specifically designed web-tool ELF library proposals parameters and measures.
Novelty: no matches against the existing JECL collection, previously accepted JECL libraries, a collation of commercial vendor sources (http://www.int-conf-chem-structures.org/ fileadmin/user_upload/ICCS_2014/posters/P22-Kalliokoski.pdf ), and additional chemistryoriented repositories based on the patent literature [14] . Molecular properties: contemporary drug-like properties [15] . Diversity potential: number of diversification points (at least two) and their practical exploitation.
Structural features: absence of chemical liabilities as defined by a collection of substructure filters contributed by the pharmaceutical companies participating in the ELF [10] . Synthetic tractability: cost of goods, atom economy, length and efficiency of the synthetic route, and associated purification and diversification steps. Innovation: original library design (structural and synthetic levels) rationale and concept.
compounds meeting the Joint European Compound Library (JECL) quality criteria for purity (LC-MS purity >85%) and quantity (>5 mmol) are then added to the JECL and plated for the ELF HTS. The ELF compound management groups routinely perform standard sample analyses to monitor compound purity, solubility and structural identity, and ensure adequate sample quality for biological screening purposes. The synthesized amounts have been defined so that each sample is available to all HTS campaigns and relevant follow-up activities during the course of the ELF project, without the need for its resynthesis. Additionally, each principal investigator who receives a qualified hit-list at the end of an ELF HTS and hit evaluation campaign could access the relevant physical samples and associated synthetic procedures for the compounds in the qualified hit-list to jump-start additional research efforts. Each hit compound appearing on such qualified hit-lists will be automatically removed from the JECL collection, as a way to protect the intellectual property of the principal investigator. Data sharing across the various ELF chemistry consortium partners, from the original library enumeration performed by the Lead Discovery Center, to experimental validation procedures from academic and SME groups, to the shipment of the final compounds to the screening centers from each SME, is facilitated by Tarosgate, a chemistry management solution especially designed for the ELF project.
Compound-level analysis
A total of 54,831 final compounds has been successfully delivered to the ELF compound management facilities and distributed to the ELF screening centers, with an average LC-MS purity of 97% and average 16 mmol amount, as detailed in Fig. 1 . Industrial and academic chemists have designed and validated libraries that contributed 57% and 43% of these compounds, respectively. Overlap analysis of the screening collections considered here reveals the PCC set to be unique, with no duplicate structures identified in the Maybridge collection, the MLP or ChEMBL.
Compounds in the PCC set are also structurally dissimilar to each other, as summarized in Fig. 1 . Here, the average Tanimoto coefficient based on extended connectivity fingerprints (ECFP6) is 0.17. As a reference, compounds in the diversitybased Maybridge library have a maximum Tanimoto coefficient of 0.2 when using the same ECFP6 metric. Furthermore, the PCC compounds are significantly dissimilar from existing compounds in the other collections considered in the present study. Intercollection similarity is less than 0.2 for the PCC set compounds when compared with MPL-NIH, Maybridge and the ChEMBL database, as described in Fig. 1 .
The distributions of molecular descriptors commonly used in medicinal chemistry are shown in Fig. 2 for the PCC set, the Maybridge screening collection, the MLP library and the ChEMBL compound bank. Overall, all libraries share typical Lipinski rule-of-five [14] attributes. Here, the PCC library displays the highest polarity and molecular weight. In total, 85% of the PCC compounds have c log P values less than 4 compared with 80% for MLP, 62% for Maybridge and 67% for ChEMBL compounds. In addition, 58% of the PCC compounds have a molecular mass greater than 400 Da (MLP, 30%; Maybridge, 21%, ChEMBL, 46%). The major differences between the libraries emerge when the number of chiral centers and the fraction of sp 3 hybridized carbon atoms (Fsp 3 ) are considered. 85% of the PCC compounds are chiral with 62% of them having two or more chiral centers (cf. Maybridge, 3%; MLP, 9% and ChEMBL, 22%). PCC compounds also have an increased 3D character, with 68% displaying Fsp 3 greater than 0.4 (cf.
Maybridge, 15%; MLP, 29% and ChEMBL, 34%). This translates as a marked difference at a molecular-shape level. When the 3D conformations of the final compounds were analyzed using the molecular principal moments of inertia (PMI) [15] and plane of best fit (PBF) [16] methods (see the supplementary material online), PCC compounds demonstrated a significantly less flat and more globular ('sphere-like') shape compared with compounds in any of the databases evaluated in the present study (Fig. 2) .
Scaffold level analysis
The PCC compounds originate from a total of 106 library proposals, yielding an average size of library of 521 compounds (Fig. 1) . Each library proposal is normally defined by a scaffold, that is, a molecular template that is chemically modified in a systematic fashion at given positions (diversity points). Of the 106 unique PCC scaffolds, 73 (69%) contain at least three diversity points that have been derivatized during library production (Fig. 3) . Most PCC scaffolds tend to be compact (80% with molecular weight <200 Da) and polar (70% with TPSA of 40-80 Å 2 ). Furthermore, the carbon atoms in the PCC scaffolds are mostly sp 3 hybridized (Fsp 3 > 0.4 for 86% of the PCC library cores) and two or more chiral atoms are present in 70% of their structures, as shown in Fig. 3 . The structural similarity among scaffolds is also low, with average and maximum Tanimoto coefficients of 0.09 and 0.5, respectively (Fig. 3f) .
Framework level analysis
Bemis-Murcko [17] scaffold analysis (see the supplementary material online) was then used to evaluate the 2D shape and topology of the PCC compounds. These are described by a total of 366 unique frameworks. Overlap analysis of the frameworks across the different compound sets studied here indicated that only 27% of the PCC frameworks (N = 99) are shared across the PCC, Maybridge, NIH and ChEMBL collections. Interestingly, 56% of the PCC frameworks (N = 204) are unique, as detailed in Fig. 4 .
Discussion
After an initial preparatory phase dedicated to recruitment, infrastructure set-up, workflow evaluation and trust building, the ELF chemistry consortium is now fully operational and actively working toward the goal of synthesizing circa 200,000 novel, attractive compounds for biochemical HTS purposes by the end of 2017. As of March 2015, this had resulted in the successful synthesis, purification and delivery of 54,831
final compounds to the ELF screening centers. As described here, the delivered samples are well suited for HTS applications, being available in sufficient quantities to allow up to 240 HTS campaigns to be executed without sample depletion and in outstanding chemical purity, thus reducing the occurrence of screening false positives and greatly simplifying results interpretation, deconvolution and decision making during hit evaluation. The PCC compounds originate from a librarybased approach where congeneric series of compounds are obtained through derivatization of a common scaffold. Selection of diversity reagents in the ELF aims at ensuring a good balance between the availability of related
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FIGURE 2
Comparitive inter-and intra-collection compound collection analysis. (a) Molecular weight, (b) calculated log P (c log P), (c) number of chiral centers, (d) number of rotatable bonds, (e) topological polar surface area (TPSA) and (f) fraction of sp 3 -hybridized carbon atoms profiles for Public Compound Collection (PCC) (red bars), Molecular Library Program (MLP) (black bars), Maybridge (dark-gray bars) and ChEMBL (light-gray bars) compounds. Cumulative distributions of distances from canonical sphere (g) and flat (h) shapes using principal moments of inertia (PMI) and plane of best fit (PBF) descriptors, respectively, for PCC (red diamonds), MLP (black circles), Maybridge (dark-gray squares) and ChEMBL (light-gray triangles) compounds.
www.drugdiscoverytoday.com 1313 pairs of molecules to discern structure-activity relationships (SAR) during hit evaluation and wide sampling of chemical space. Accordingly, the PCC compounds have a low level of structural redundancy, as measured by nearest neighbor similarity, which is comparable to that observed in the Maybridge set, a diversity-based collection in the strictest sense. Importantly, this degree of structural dissimilarity at a final compound level is also observed at a scaffold level. All the library scaffolds synthesized thus far differ significantly from each other, and this further increases the structural diversity and chemical space coverage of the PCC set.
Although preferred extents of physicochemical properties in drug discovery applications are a matter of debate, these are monitored throughout the ELF process. As a result, the profile of the PCC compounds does not significantly deviate from commonly accepted properties trends in the field [14, 18] . Here, a focus on maintaining a low lipophilicity character is evident because of its perceived importance in the subsequent hit development and lead optimization phases. This is especially important given that a significant portion (45%) of the PCC compounds have molecular weight of 400-500 Da. Some of these compounds are aiming at addressing challenging target classes (e.g. protein-protein interactions) with innovative chemotypes. Complex natural products have also been used as starting points for library design, thus intrinsically increasing the weight of the resulting compounds. In an effort to maximize the structural diversity of each library, the ELF consortium has been favoring designs with three or more diversification points, which has also yielded compounds with a modest increase in weight. Nevertheless, it is anticipated that reduced lipophilicity could also be beneficial in these higher molecular weight instances. [ ( F i g u r e _ 4 ) T D $ F I G ] A distinctive characteristic of the synthesized PCC set is their high level of structural complexity and three-dimensionality, two features that are regarded as attractive in drug discovery application [19, 20] . Given that most PCC compounds are chiral molecules with nonaromatic, nonplanar moieties and a strong propensity for a globular shape, their systematic screen against biological systems will prove useful in further understanding the general relevance of such compound characteristics, especially when confirmed hit rates, target class and developability considerations are taken into account. When comparing final compounds and scaffolds profiles, it is interesting to note that the polarity, structural complexity and 3D elements have been engineered in the scaffolds rather than deriving entirely from the subsequent chemical decoration. Given that the PCC scaffolds tend to be small, polar and chiral with a high 3D character, they provide versatile starting points and ample opportunities for further chemical exploration and growth during the hit-to-lead phase, based on the specific biological target and/or therapeutic area requirements.
A strong focus of the ELF chemistry consortium is to populate areas of chemical space that are not directly accessible from commercial sources or the scientific literature. Thus, no structural overlap with the Maybridge, MLP or ChEMBL databases is observed. Importantly, the similarity of the PCC compounds to any of the collections analyzed here is also limited, highlighting the complementary nature of the PCC compounds in terms of chemical space distribution. The high novelty attribute of the PCC compounds is also apparent when structural shape and topology is considered. A large proportion of the PCC frameworks are absent in the compound collections analyzed here. Indeed, a significant number of unprecedented spiro, bridged and fused polycycles with different degrees of saturation, conjugation and substitution have been synthesized and expanded to a library format. This has been recently exemplified by several publications from the ELF chemistry groups detailing the associated design and validation aspects [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . Given that most theoretical ring systems remain unexplored [39] , the synthesis of novel rings represents one of the strategies embraced by the ELF chemistry consortium to expand the available chemical space.
Concluding remarks
Given that large-scale screening continues to be a practical and productive entry to successful drug discovery [40, 41] , the availability of a novel, high-quality screening collection cannot be emphasized enough [42] . During the past year and a half of work, the ELF Chemistry Consortium has implemented an innovative compound library factory based on a collaborative approach between chemistry-focused academic groups and SMEs. This has resulted in an effective pooling of complementary ideas, solutions and resources to carry out high-risk chemistry research to explore unprecedented areas of chemical space that are relevant to biological screening. These efforts have yielded diverse and distinctive compounds that will properly complement existing public and proprietary compound collections for HTS drug discovery applications. Building on intersectoral, complementary strengths and expertise, this offers a practical blueprint for future compound collection enhancement campaigns in the everlasting quest for novel chemical space.
